Study to evaluate safety and efficacy of induction therapy with antithymocyte-globulin and basiliximab for prevention of delayed graft function in kidney transplant recipients.
Phase of Trial: Phase IV
Latest Information Update: 19 Aug 2015
At a glance
- Drugs Antithymocyte globulin (Primary) ; Basiliximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 19 Aug 2015 New trial record